Evidence mapPaperPMID 40634815Full record

ReviewApoptosis : an international journal on programmed cell death2025

Exploiting autophagy and related pathways: pioneering new horizons in cataract therapy.

Mehrdad Hashemi, Pezhman Shafiei Asheghabadi, Mahdi Moassesfar, Roya Malek Mohammadi, Nazanin Rafedoust, Maedeh Razeh, Yeganeh Esfahaniolasl, Mahsa Mirzayi, Sahar Keikhavani, Katrin Tajbakhsh and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Cataract: Surgery first - is there still room for basic research?Advances in ophthalmology practice and research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mehrdad HashemiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Pezhman Shafiei AsheghabadiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Mahdi MoassesfarFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Roya Malek MohammadiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Nazanin RafedoustFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Maedeh RazehFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Yeganeh EsfahaniolaslFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Mahsa MirzayiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Sahar KeikhavaniFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Katrin TajbakhshFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran.
Hajar HeidariDepartment of Biomedical Sciences, School of Public Health University at Albany State University of New York, Albany, NY, 12208, USA.
Russel J ReiterDepartment of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX, 78229, USA.
Mina AlimohammadiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Mina.alimohammadi11@gmail.com.
Afshin TaheriazamFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran. a.taheriazam@iautmu.ac.ir.
Najma FarahaniFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran. Najmafarahani@gmail.com.
Kiavash HushmandiDepartment of Epidemiology, University of Tehran, Tehran, Iran. Houshmandi.kia7@ut.ac.ir.
Maliheh EntezariFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, TMs.C., Islamic Azad University, Tehran, Iran. mentezari@iautmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy is a critical catabolic pathway that facilitates the degradation of intracellular components through lysosomal activity, originally recognized for its role in nutrient recycling during starvation. Recent research has expanded our understanding of autophagy, revealing its involvement in various physiological processes essential for cellular, tissue, and organismal homeostasis. Dysregulation of autophagy has been linked to numerous diseases, including ocular conditions such as cataracts. In human lens fibers, autophagic vesicles containing mitochondria or mitochondrial fragments have been identified, underscoring the importance of autophagy in maintaining lens integrity and transparency. Disruptions in organelle elimination can lead to increased reactive oxygen species (ROS), altering lens homeostasis and contributing to cataract formation. Recent studies have highlighted the complex interplay between autophagy and lens epithelial cells (LECs) in both age-related and diabetic cataract development. In age-related cataracts, increased autophagic activity coincides with elevated apoptosis in LECs, suggesting a bidirectional regulatory role of autophagy in cellular senescence. Additionally, the degradation of SQSTM1/p62 during oxidative stress implicates autophagy in the apoptotic processes associated with senile cataracts. In diabetic cataracts, high glucose levels disrupt the relationship between autophagy and epithelial-mesenchymal transition (EMT) in LECs via the Notch signaling pathway, leading to impaired autophagic function and subsequent cataractogenesis. These findings indicate that autophagy dysregulation is a significant contributor to the pathophysiology of various cataract types. Future research should focus on exploring the therapeutic potential of modulating autophagy to prevent or treat cataracts, investigating specific signaling pathways involved, and identifying biomarkers for early detection. By elucidating the molecular mechanisms underlying autophagy's role in cataract formation, novel targeted therapies may emerge, providing hope for improved management and prevention of this prevalent ocular pathology.

Indexed as

AutophagyCataractAnimalsApoptosisEpithelial CellsEpithelial-Mesenchymal TransitionHumansLens, CrystallineOxidative StressReactive Oxygen SpeciesSignal TransductionReactive Oxygen SpeciesAutophagyCataractEpithelial-mesenchymal transitionLens epithelial cellsOxidative stress

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.